LBF20115PG02: Difference between revisions
No edit summary |
No edit summary |
||
| (18 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
| Line 4: | Line 6: | ||
|LipidBank=XPR1712 | |LipidBank=XPR1712 | ||
|LipidMaps=LMFA03010031 | |LipidMaps=LMFA03010031 | ||
|SysName=9,15- | |SysName=9,15-Dioxo-11alpha-hydroxy-prost-cis-5-en-1-oic acid | ||
|Common Name=&&13,14-dihydro- | |Common Name=&&13,14-dihydro-15-keto Prostaglandin E_2&&9,15-Dioxo-11alpha-hydroxy-prost-5(Z)-en-1-oic acid&& | ||
|Source=13,14-dihydro-15keto PGE2 is the primary metabolite of PGE2 in plasma via PG 15-dehydrogenase.[[Reference:Hamberg_M:Samuelsson_B:,J. Biol. Chem.,1971,246,6713|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Samuelsson_B:,J. Biol. Chem.,1971,246,6713}}]] | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
}} | }} | ||
{{Lipid/Footer}} | |||
Latest revision as of 17:18, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1712 |
| LipidMaps | LMFA03010031 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20115PG02 |
| 13,14-dihydro-15-keto Prostaglandin E2 | |
|---|---|
| |
| Structural Information | |
| 9,15-Dioxo-11α-hydroxy-prost-cis-5-en-1-oic acid | |
| |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | CCCCCC(=O)CCC(C(O)1)C(CC=CCCCC(O)=O)C(=O)C1 |
| Physicochemical Information | |
| 13,14-dihydro-15keto PGE2 is the primary metabolite of PGE2 in plasma via PG 15-dehydrogenase. Hamberg_M et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
